{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:14:39Z","timestamp":1787505279670,"version":"build-2736575974"},"reference-count":51,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Guidelines recommend biomarker testing and biomarker-informed therapies in patients with metastatic non\u2013small cell cancer (mNSCLC); however, the use remains suboptimal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>To understand contemporary testing and treatment patterns, retrospective data from 42,037 patients with mNSCLC in a nationwide electronic health record\u2013derived deidentified database from January 2011 to April 2023 were used to quantify testing rates, test positivity, and use of biomarker-informed therapies, stratified by key demographics to identify potential disparities. Multivariable logistic regression was conducted to include patient characteristics associated with the receipt of biomarker testing and subsequent biomarker-informed therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      A total of 34,510 patients (82.1%) received \u2265one biomarker test(s). Biomarker testing and use of biomarker-informed therapies increased for all studied biomarkers (\n                      <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">ROS1<\/jats:italic>\n                      , PD-L1,\n                      <jats:italic toggle=\"yes\">BRAF<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">RET<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">MET<\/jats:italic>\n                      ) over time, with highest rates observed in 2023:\n                      <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n                      (88.7% and 79.5%, respectively) and\n                      <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                      (87.7% and 84.3%, respectively). In multivariate logistic regression, patient sex, race, Eastern Cooperative Oncology Group at baseline, insurance type, smoking status at baseline, and histology were all significantly associated with odds of receiving biomarker testing. Covariates statistically associated with receipt of biomarker-informed therapy varied by biomarker without a clear pattern of association. Although the use of biomarker testing and biomarker-informed therapies has increased in recent years, gaps and potential disparities remain.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Analysis of contemporary trends in biomarker testing and use of targeted therapies in mNSCLC in the United States highlight improvements in recent years. However, these rates remain suboptimal in specific strata of the patient population, including differences in racial groups and insurance groups, indicating further work is needed to bridge remaining gaps.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/po-24-00449","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T15:59:14Z","timestamp":1747324754000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":11,"title":["Real-World Analysis of Disparities in Biomarker Testing and Use of Recommended Targeted Therapies in Metastatic Non\u2013Small Cell Lung Cancer in the United States"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8175-5311","authenticated-orcid":true,"given":"Michael J.","family":"Dennis","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Abrahami","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cecilia","family":"Vieira","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4537-1863","authenticated-orcid":true,"given":"Darrin","family":"Benjumea","sequence":"additional","affiliation":[{"name":"Genesis Research, LLC, Hoboken, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marley","family":"Boyd","sequence":"additional","affiliation":[{"name":"Genesis Research, LLC, Hoboken, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9693-9878","authenticated-orcid":true,"given":"Anran","family":"Shao","sequence":"additional","affiliation":[{"name":"Genesis Research, LLC, Hoboken, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kelton","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8387-4840","authenticated-orcid":true,"given":"Sandip Pravin","family":"Patel","sequence":"additional","affiliation":[{"name":"UC San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_6_2_2","unstructured":"American Cancer Society key statistics for lung cancer 2023"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"e_1_3_6_4_2","volume-title":"Non-Small Cell Lung Cancer Treatment (PDQ)-Health Professional Version","author":"NIH","year":"2024","unstructured":"NIH: Non-Small Cell Lung Cancer Treatment (PDQ)-Health Professional Version. Bethedsa, MD, National Cancer Institute, NIH, 2024"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0467"},{"key":"e_1_3_6_6_2","article-title":"Biomarker discovery and outcomes for comprehensive cell-free circulating tumor DNA versus standard-of-care tissue testing in advanced non-small-cell lung cancer","author":"Palmero R","unstructured":"Palmero R, Taus A, Viteri S, et al: Biomarker discovery and outcomes for comprehensive cell-free circulating tumor DNA versus standard-of-care tissue testing in advanced non-small-cell lung cancer. JCO Precis Oncol 10.1200\/PO.20.00241","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.478"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01989"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2010.000166"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_237863"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2016.08.012"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29020057"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2322"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.9638"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2017.11.004"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy474"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01617-2"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2017.04.004"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.03.004"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0540"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-23-407"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.27204"},{"key":"e_1_3_6_23_2","article-title":"Disparities in biomarker testing and clinical trial enrollment among patients with lung, breast, or colorectal cancers in the United States","author":"Bruno DS","unstructured":"Bruno DS, Hess LM, Li X, et al: Disparities in biomarker testing and clinical trial enrollment among patients with lung, breast, or colorectal cancers in the United States. JCO Precis Oncol 10.1200\/PO.21.00427","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","unstructured":"Ma X Long L Moon S et al: Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health SEER and NPCR. medRxiv 10.1101\/2020.03.16.20037143","DOI":"10.1101\/2020.03.16.20037143"},{"key":"e_1_3_6_25_2","unstructured":"BoehringerIngelheim: GILOTRIF\u00ae (afatinib)\u2014Highlights of prescribing information. FDA U 2019"},{"key":"e_1_3_6_26_2","unstructured":"AstraZeneca: IRESSA (gefitinib)\u2014Highlights of prescribing information. FDA U 2018"},{"key":"e_1_3_6_27_2","unstructured":"Genentech: TARCEVA (erlotinib)\u2014Highlights of prescribing information. FDA U 2016"},{"key":"e_1_3_6_28_2","unstructured":"AstraZeneca: TAGRISSO\u00ae (osimertinib)\u2014Highlights of prescribing information. FDA U 2024"},{"key":"e_1_3_6_29_2","unstructured":"Pfizer: VIZIMPRO\u00ae (dacomitinib)\u2014Highlights of prescribing information. FDA U 2020"},{"key":"e_1_3_6_30_2","unstructured":"Takeda: EXKIVITY\u2122 (mobocertinib)\u2014Highlights of prescribing information. FDA U 2021"},{"key":"e_1_3_6_31_2","unstructured":"Janssen: RYBREVANT\u00ae (amivantamab-vmjw)\u2014Highlight prescribing information. FDA U 2024"},{"key":"e_1_3_6_32_2","unstructured":"Pfizer: XALKORI\u00ae (crizotinib)\u2014Highlights of prescribing information. FDA U 2023"},{"key":"e_1_3_6_33_2","unstructured":"Novartis: ZYKADIA\u00ae (ceritinib)\u2014Highlight of prescribing information. FDA U 2021"},{"key":"e_1_3_6_34_2","unstructured":"Genentech: ALECENSA\u00ae (alectinib)\u2014Highlights of prescribing information. FDA U 2024"},{"key":"e_1_3_6_35_2","unstructured":"Takeda: ALUNBRIG\u00ae (brigatinib)\u2014Highlights of prescribing information. FDA U 2022"},{"key":"e_1_3_6_36_2","unstructured":"Pfizer: LORBRENA\u00ae (lorlatinib)\u2014Highlights of prescribing information. FDA U 2023"},{"key":"e_1_3_6_37_2","unstructured":"Genentech: ROZLYTREK\u00ae (entrectinib)\u2014Highlights of prescribing information. FDA U 2024"},{"key":"e_1_3_6_38_2","unstructured":"Novartis: TABRECTA\u00ae (capmatinib)\u2014Highlights of prescribing information. FDA U 2024"},{"key":"e_1_3_6_39_2","unstructured":"Novartis: TAFINLAR\u00ae (dabrafenib)\u2014Highlights of prescribing information. FDA U 2024"},{"key":"e_1_3_6_40_2","unstructured":"Novartis: MEKINIST\u00ae (trametinib)\u2014Highlights of prescribing information. FDA U 2024"},{"key":"e_1_3_6_41_2","unstructured":"Genentech: GAVRETO\u00ae (pralsetinib)\u2014Highlights of prescribing information. FDA U 2023"},{"key":"e_1_3_6_42_2","unstructured":"EliLilly: RETEVMO (selpercatinib)\u2014Highlights of prescribing information. FDA U 2022"},{"key":"e_1_3_6_43_2","unstructured":"Merck: KEYTRUDA\u00ae (pembrolizumab)\u2014Highlights of prescribing information. FDA U 2024"},{"key":"e_1_3_6_44_2","unstructured":"Regeneron: LIBTAYO\u00ae (cemiplimab-rwlc)\u2014Highlights of prescribing information. FDA U 2024"},{"key":"e_1_3_6_45_2","unstructured":"Genentech: TECENTRIQ\u00ae (atezolizumab)\u2014Highlights of prescribing information. FDA U 2024"},{"key":"e_1_3_6_46_2","unstructured":"BMS: OPDIVO (nivolumab)\u2014Highlights of prescribing information. FDA U 2024"},{"key":"e_1_3_6_47_2","unstructured":"BMS: YERVOY\u00ae (ipilimumab)\u2014Highlights of prescribing information. FDA U 2023"},{"key":"e_1_3_6_48_2","unstructured":"AstraZeneca: IMJUDO\u00ae (tremelimumab-actl)\u2014Highlights of prescribing information. FDA U 2023"},{"key":"e_1_3_6_49_2","unstructured":"AstraZeneca: IMFINZI\u00ae (durvalumab)\u2014Highlights of prescribing information. FDA U 2023"},{"key":"e_1_3_6_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697"},{"key":"e_1_3_6_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100336"},{"key":"e_1_3_6_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2022.100522"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-24-00449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T15:59:26Z","timestamp":1747324766000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-24-00449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1200\/PO-24-00449"],"URL":"https:\/\/doi.org\/10.1200\/po-24-00449","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"2024-07-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2400449"}}